Cells can often be recognized by the concentrations of receptors expressed on their surface. For better (targeted drug treatment) or worse (targeted infection by pathogens), it is clearly important to be able to target cells selectively. A good targeting strategy would result in strong binding to cells with the desired receptor profile and barely binding to other cells. Using a simple model, we formulate optimal design rules for multivalent particles that allow them to distinguish target cells based on their receptor profile. We find the following: (i) It is not a good idea to aim for very strong binding between the individual ligands on the guest (delivery vehicle) and the receptors on the host (cell). Rather, one should exploit multivalency: High sensitivity to the receptor density on the host can be achieved by coating the guest with many ligands that bind only weakly to the receptors on the cell surface.(ii) The concentration profile of the ligands on the guest should closely match the composition of the cognate membrane receptors on the target surface. And (iii) irrespective of all details, the effective strength of the ligand-receptor interaction should be of the order of the thermal energy k B T, where T is the absolute temperature and k B is Boltzmann's constant. We present simulations that support the theoretical predictions. We speculate that, using the above design rules, it should be possible to achieve targeted drug delivery with a greatly reduced incidence of side effects.T he fact that most cells can be recognized from the outside is advantageous for the normal functioning of an organism, but it can be a disadvantage when specific cells are being targeted by pathogens. Cells betray their identity (and state of health) by the composition profile of molecules that are exposed on their outer surface. In what follows, we call these molecules "receptors," irrespective of whether they are receptors in the biological sense (they are receptors for the ligands that will be used to recognize them). It would clearly be advantageous if diseased cells could be selectively targeted by a drug-delivery vehicle on the basis of their receptor profile. Here, the crucial word is "selective": We wish to target only those cells that have the correct receptor profile, as binding of drug-delivery vehicles to other cells may lead to undesired side effects.Targeted drug delivery is based on identifying a specific marker (peptide, sugar) that is unique to the targeted group of cells. Binding to a single marker type can be effective if this molecule is presented in sufficient quantities on the outer surface of the targeted cell. However, in many cases of practical importance (e.g., many types of cancer), the markers that are known are not unique to cancer cells, but just overexpressed. Over the past 20 y many nanoparticle-based targeting methods have been developed. However, thus far, effective tumor drug delivery is hampered by the lack of reliable, unique markers (1, 2).To recognize the simultaneous presence of a mixture o...